Big Pharma's Biggest Trade Group Just Sued the Federal Government

The relief PhRMA wants is simple: declare the whole thing unlawful and throw it out.

The Catch That Makes This Weirder

Here's where the story gets interesting. The GLOBE rule might not actually apply to very many companies. CMS has said it will waive the policy for manufacturers that sign separate voluntary pricing agreements with the White House. In other words, if a drugmaker cuts a deal directly with the administration, the international benchmarking doesn't kick in.

That means the rule may only land on a handful of holdouts who refuse to negotiate. It's a bit like passing a speed limit that only applies to drivers who won't agree to slow down voluntarily. The practical reach is limited, but the principle at stake is enormous.

For Wall Street, this probably means limited near-term earnings impact for most pharma companies. But investors aren't watching this case for next quarter's numbers. They're watching it because a court ruling in favor of CMS would validate a powerful new tool for the federal government to control drug prices, one that could be expanded far beyond this initial pilot.

A Battle-Tested Industry (With a Losing Record)

PhRMA has been here before, and the recent track record isn't great.

When Congress passed the Inflation Reduction Act (IRA) in 2022, it gave Medicare the power to negotiate drug prices directly for the first time. The industry launched a massive legal campaign starting in 2023: Merck, Bristol Myers Squibb, Janssen, Astellas, and PhRMA itself all filed lawsuits challenging the program on constitutional grounds. They argued it violated the First Amendment (compelled speech), the Fifth Amendment (taking property without compensation), and more.

Courts weren't convinced. Judges repeatedly pointed out that participation in Medicare is voluntary; nobody forces a drug company to sell to Medicare. By May 2026, the Supreme Court denied all six petitions from manufacturers trying to overturn the IRA's negotiation program. The first wave of legal challenges was effectively dead.

The first negotiated prices under the IRA took effect in January 2026, covering ten drugs. A second batch of 15 drugs will see negotiated prices in 2027, with another round following in 2028. The program is rolling, and so far, courts have let it roll.

Why This Fight Is Different

The GLOBE lawsuit targets a different legal vulnerability than the IRA challenges. PhRMA isn't arguing that Congress can't authorize drug price negotiations (that argument already lost). Instead, the claim is that CMS went rogue, using narrow demonstration authority to impose something Congress never approved.

It's a much more focused attack, and it sidesteps the "Medicare is voluntary" defense that doomed earlier cases. The question isn't whether the government can set drug prices; it's whether this particular agency, through this particular mechanism, had the authority to do it without Congress explicitly saying so.

That distinction matters. Courts have been increasingly skeptical of federal agencies stretching their authority beyond what statutes clearly permit (a trend reinforced by recent Supreme Court rulings on administrative power). PhRMA may have found better legal ground this time around.

The Bigger Picture

This case will likely take months or years to resolve, but its significance extends well beyond the GLOBE rule itself. If the court sides with the administration, it would signal that CMS can use demonstration programs as a vehicle for sweeping pricing reforms without new legislation. That would give future administrations (of either party) a powerful shortcut around Congress.

If the court sides with PhRMA, it would put a hard limit on how far CMS can push pricing experiments. Future drug pricing reforms would need to go through Capitol Hill, where the pharmaceutical industry has historically wielded enormous lobbying influence.

For drugmakers, the strategic calculation right now is simple: cut a voluntary deal with the White House and avoid the GLOBE rule entirely, or hold out and hope the courts come to the rescue. Given the industry's recent losing streak in drug pricing litigation, that's a gamble with serious downside.

The pharmaceutical industry spent years fighting drug pricing reform in court and losing. Now it's back for another round, swinging at a different target with a different legal theory. Whether that's strategic evolution or stubbornness dressed up in a new suit, only the courts will decide.

Why Telix Just Paid $2.35 Billion for a Factory

Telix Pharmaceuticals is spending up to $2.35 billion to acquire ITM Isotope Technologies, and the real story isn't the pipeline. It's a high-stakes bet on controlling the fragile supply chain that the entire radiopharmaceutical industry depends on.